Biogen Idec Research Limited

Neurodegenerative disease and motor neuron disorders

Research activity includes spinal muscular atrophy, amyotrophic lateral sclerosis linked to SOD1 mutation, Parkinson’s disease, and mild cognitive impairment due to Alzheimer’s disease.

  • Spinal muscular atrophy
  • Amyotrophic lateral sclerosis with SOD1 mutation
  • Parkinson’s disease
  • Alzheimer’s disease–related cognitive decline

The portfolio also extends to long-term neurological follow-up and treatment persistence in inherited and progressive nervous system disorders.

Multiple sclerosis and central nervous system inflammation

Clinical research covers relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis and pediatric RRMS, with attention to inflammatory activity within the central nervous system.

  • Relapsing-remitting multiple sclerosis
  • Relapsing forms of multiple sclerosis
  • Pediatric multiple sclerosis
  • Brain inflammation and MRI-defined disease activity

Work in this area also includes continued evaluation of disease control and longer-term neurological outcomes.

Lupus and cutaneous autoimmune disease

The sponsor funds studies in systemic lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus, including cases with systemic features and refractory skin disease.

  • Systemic lupus erythematosus
  • Subacute cutaneous lupus erythematosus
  • Chronic cutaneous lupus erythematosus
  • Autoimmune skin and systemic manifestations

These studies focus on both skin activity and broader autoimmune involvement in adult populations.

Kidney transplantation and immune-mediated renal disease

Research includes kidney transplant recipients with late antibody-mediated rejection and microvascular inflammation, alongside primary renal autoimmunity such as IgA nephropathy.

  • Late antibody-mediated rejection
  • Late isolated microvascular inflammation
  • IgA nephropathy
  • Transplant-related immune injury

The renal portfolio reflects interest in both post-transplant complications and chronic immune-driven kidney disease.

Inherited retinal disease and rare genetic disorders

Additional studies address choroideremia, X-linked retinitis pigmentosa, and Friedreich’s ataxia, highlighting involvement in inherited conditions affecting vision and neurology.

  • Choroideremia
  • X-linked retinitis pigmentosa
  • Friedreich’s ataxia
  • Rare genetic disease

These programs include disorders with progressive sensory, retinal, and neurologic impairment.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of BIIB115 in patients aged 15‑60 years with spinal muscular atrophy who are treatment‑naïve or previously treated with risdiplam

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    Finland France Germany Ireland Italy Poland +1
  • Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Nonbiologic Standard of Care: A Phase 3 Randomized Controlled Trial

    Not recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria France Greece Poland Spain Sweden
  • Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

    Not recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Czechia Germany Hungary Italy The Netherlands +1
  • Study on the Safety and Tolerability of BIIB115 for Children with Spinal Muscular Atrophy Previously Treated with Gene Therapy

    Not recruiting

    1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy The Netherlands Poland
  • Study on Higher Doses of Nusinersen for Patients with Spinal Muscular Atrophy Who Previously Participated in a Nusinersen Study

    Not recruiting

    3 1 1
    Investigated Drugs:
    Germany Italy Spain
  • Study of Tofersen for Adults with Presymptomatic Amyotrophic Lateral Sclerosis (ALS) Due to SOD1 Gene Mutation

    Not recruiting

    3 1
    Investigated Drugs:
    France Germany Italy Poland Spain Sweden